Netakimab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Netakimab is a monoclonal antibody used in the treatment of various autoimmune diseases. It is specifically designed to target and inhibit interleukin-17 (IL-17), a pro-inflammatory cytokine involved in the pathogenesis of several inflammatory conditions.
Mechanism of Action[edit | edit source]
Netakimab functions by binding to IL-17, thereby preventing it from interacting with its receptor on the surface of target cells. This inhibition reduces the inflammatory response mediated by IL-17, which is implicated in diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. By blocking IL-17, netakimab helps to alleviate the symptoms associated with these conditions.
Clinical Uses[edit | edit source]
Netakimab is primarily indicated for the treatment of:
- Psoriasis: A chronic autoimmune condition characterized by red, scaly patches on the skin.
- Ankylosing spondylitis: A type of arthritis that affects the spine and large joints.
- Psoriatic arthritis: An inflammatory arthritis associated with psoriasis.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of netakimab includes its absorption, distribution, metabolism, and excretion. As a monoclonal antibody, it is typically administered via subcutaneous injection. The bioavailability and half-life of netakimab are consistent with other monoclonal antibodies, allowing for dosing at regular intervals to maintain therapeutic levels.
Adverse Effects[edit | edit source]
Common adverse effects of netakimab include:
- Injection site reactions
- Upper respiratory tract infections
- Headache
Serious adverse effects may include:
- Increased risk of infections
- Hypersensitivity reactions
Regulatory Status[edit | edit source]
Netakimab has been approved for use in several countries for the treatment of the aforementioned conditions. Its approval is based on clinical trials demonstrating its efficacy and safety profile.
Research and Development[edit | edit source]
Ongoing research is exploring the potential of netakimab in other inflammatory and autoimmune diseases. Studies are also investigating its long-term safety and efficacy.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
